29 June 2017 - After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination on baricitinib for moderate to severe rheumatoid arthritis and submitted it to the Institute.

Baricitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with conventional disease-modifying anti-rheumatic drugs (DMARDs), only if:

• disease is severe (a disease activity score [DAS28] of more than 5.1) and
  
• the company provides baricitinib with the discount agreed in the patient access scheme.
  

Baricitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:

• disease is severe (a DAS28 of more than 5.1) and
  
• they cannot have rituximab and
  
• the company provides baricitinib with the discount agreed in the patient access scheme.
  

Read NICE Final Appraisal Determination for baricitinib